The PE Ratio as of November 2024 (TTM) for Liquidia Corporation (LQDA) is -6.57

According to Liquidia Corporation’s latest financial reports and current stock price. The company's current PE Ratio is -6.57. This represents a change of -14.48% compared to the average of -7.68 of the last 4 quarters.

Liquidia Corporation (LQDA) Historical PE Ratio (quarterly & annually)

How has LQDA PE Ratio performed in the past?

The mean historical PE Ratio of Liquidia Corporation over the last ten years is -5.17. The current -6.57 PE Ratio has changed 12.60% with respect to the historical average. Over the past ten years (40 quarters), LQDA's PE Ratio was at its highest in in the December 2017 quarter at 2.90. The PE Ratio was at its lowest in in the December 2022 quarter at -17.22.

Liquidia Corporation (LQDA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Liquidia Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Liquidia Corporation (LQDA) Average PE Ratio

How has LQDA PE Ratio performed in the past?

The current PE Ratio of Liquidia Corporation (LQDA) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Liquidia Corporation (LQDA) PE Ratio vs. Peers

How is LQDA’s PE Ratio compared to its peers?

Liquidia Corporation’s PE Ratio is less than BioMarin Pharmaceutical Inc. (37.97), greater than Vaxcyte, Inc. (-21.57), greater than Legend Biotech Corporation (-21.42), less than Bio-Techne Corporation (74.98), less than United Therapeutics Corporation (14.97), greater than Geron Corporation (-13.39), less than NRx Pharmaceuticals, Inc. (-0.68), less than Agenus Inc. (-0.32), less than Replimune Group, Inc. (-5.51), less than Nuvectis Pharma, Inc. (-4.54), less than Lyra Therapeutics, Inc. (-0.13), less than Kronos Bio, Inc. (-0.64), less than Gossamer Bio, Inc. (-2.20), less than Terns Pharmaceuticals, Inc. (-5.12), less than Amylyx Pharmaceuticals, Inc. (-1.38), less than Acumen Pharmaceuticals, Inc. (-1.74), less than Inozyme Pharma, Inc. (-1.84), less than X4 Pharmaceuticals, Inc. (-4.05), greater than Immunocore Holdings plc (-30.05), greater than Mirum Pharmaceuticals, Inc. (-21.97), less than Larimar Therapeutics, Inc. (-6.07), less than KalVista Pharmaceuticals, Inc. (-3.31),

Build a custom stock screener for Liquidia Corporation (LQDA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Liquidia Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Liquidia Corporation (LQDA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Liquidia Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.